title: [Prognostic Significance of Joint Detection of miR-210 and Minimal Residual Disease in Pediatric Acute Lymphoblastic Leukemia].
abstract: OBJECTIVE
  To detect the expression of microRNA-210(miR-210) in childhood acute lymphoblastic leukemia(ALL), and to evaluate the role of the joint detection of miR-210 and MRD in the prognosis and clinical treatment of pediatric ALL.
  
  
  METHODS
  Eighty-eight children diagnosed with ALL were included in the study. miR-210 was quantitatively detected by real-time quantitative polymerase chain reaction(RQ-PCR) in 88 ALL patients. The average Ct value of samples obtained from 5 pediatric ALL patients with long-term complete continuous remission (CCR>5 years) was used as a calibrator. The expression levels of miR-210 in newly diagnosed patients was calculated by the 2-ΔΔCtmethod and presented as multiple changes compared with that of the 5 CCR patients.
  
  
  RESULTS
  The expression of miR-210 in the favorable prognosis group was significantly higher than that in the unfavorable prognosis group (10.64±1.5 vs 3.27±0.68)(P<0.05). Compared with the miR-210 high-expression group, poorer relapse-free survival(RFS), event-free survival(EFS) and overall survival(OS) (P all <0.001) were found in the low-expression group. Based on the expression of miR-210 and MRD, the 88 cases were divided into 3 groups. The relapse rate of miR-210-MRD high-risk group (70%) was significantly higher than that of the miR-210-MRD middle-risk group(6.25%) and miR-210-MRD low-risk group (2.1%). Kaplan-Meier survival analysis demonstrated that the miR-210-MRD high-risk group had poorer RFS, EFS and OS than those in other 2 groups (P all <0.01).
  
  
  CONCLUSIONS
  The expression level of miR-210 is an independent prognostic factor for pediatric ALL, and the miR-210 is a good useful indicator for predicting the relapse and induction failure of childhood ALL. Joint detection of miR-210 and MRD can help predict outcomes more precisely, thus may be used as an effective mean of determining prognosis, monitoring recurrence, and guiding treatment.
authors.affiliation: Department of Pediatrics, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China.
authors.forename: Yan-Yan
authors.initials: YY
authors.lastname: Mei
authors.affiliation: Hematologic of Oncology Center, Beijing Children's Hospital, Capital Medical University, Beijing 100045, China.
authors.forename: Zhi-Gang
authors.initials: ZG
authors.lastname: Li
authors.affiliation: Department of Pediatrics, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China.
authors.forename: Yi
authors.initials: Y
authors.lastname: Zhang
authors.affiliation: Department of Pediatrics, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China.
authors.forename: Wei-Ling
authors.initials: WL
authors.lastname: Zhang
authors.affiliation: Department of Pediatrics, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China.
authors.forename: Pin-Wei
authors.initials: PW
authors.lastname: Zhang
authors.affiliation: Department of Pediatrics, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China.
authors.forename: Nan
authors.initials: N
authors.lastname: Wang
authors.affiliation: Department of Pediatrics, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China. E-mail: hds5180@sina.com.
authors.forename: Dong-Sheng
authors.initials: DS
authors.lastname: Huang
mesh_terms: D002648:Child; D018572:Disease-Free Survival; D006801:Humans; D035683:MicroRNAs / Q000378:metabolism*; D018365:Neoplasm, Residual; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy* / Q000378:metabolism; D011379:Prognosis; D012008:Recurrence; D016896:Treatment Outcome
chemical_list: C543800:MIRN210 microRNA, human; D035683:MicroRNAs